The Latest News

Lung cancer and its prevalence in China: an Editor Q+A

Cases of lung cancer in China are rising, but why is this? Editors of a new series on lung cancer, Li Yan and Wei Zhang, explain why occurrence of lung cancer is increasing in China and the work that is being done to prevent this.

http://blogs.biomedcentral.com/on-medicine/2015/08/05/lung-cancer-preval...

Long time USCACA supporter and advisor, Dr. George Wilding, appointed vice provost for clinical and interdisciplinary research at MD Anderson Cancer Center

Long time USCACA supporter and advisor, Dr. George Wilding, appointed vice provost for clinical and interdisciplinary research at MD Anderson Cancer Center
----
HOUSTON ― The University of Texas MD Anderson Cancer Center is pleased to announce the appointment of George Wilding, M.D., as vice provost for clinical and interdisciplinary research. Dr. Wilding is a prominent prostate cancer physician-scientist who directed the University of Wisconsin’s Carbone Cancer Center (UWCCC) for 12 years. His appointment at MD Anderson begins Sept. 1.

The 7th Annual Meeting of The US Chinese Anti-Cancer Association (USCACA) at AACR 2015 in Philadelphia

Philadelphia, PA — (May 6, 2015) On April 19, 2015, more than 100 cancer researchers worldwide from academia, industry, and government agencies attended the 7th Annual USCACA Meeting at AACR 2015, organized by a committee consisting of sixteen Executive Members of the USCACA.

AFCR-funded Scientists Discover New Drug Combination to Overcome Chemotherapy Resistance in Ovarian Cancer

AFCR-funded Scientists Discover New Drug Combination to Overcome Chemotherapy Resistance in Ovarian Cancer

Shanghai-Based Biotech, Backed by Preeminent VCs, Seeks Chief Medical Officer

Shanghai-Based Biotech, Backed by Preeminent VCs, Seeks Chief Medical Officer

Occam Global is a strategic executive search firm with substantial experience serving entrepreneurial companies in the Healthcare and Technology sectors.

USCACA Board of Director Member in the News

Jan. 21st, 2015, Paris

2014 Chinese Clinical Oncology Advances Awards Announced

2014 Chinese Clinical Oncology Advances Awards Announced
From China Medical Tribune

USCACA sponsor - Chipscreen has its drug approved in China

Chipscreen Biosciences Announces CFDA Approval of Chidamide (Epidaza) for PTCLs in China
SHENZHEN, China, Jan. 09, 2015 /PRNewswire/ -- Chipscreen Biosciences today announced regulatory approval of Chidamide (Epidaza®), the world first orally administrated and subtype-selective histone deacetylase (HDAC) inhibitor for relapsed or refractory peripheral T-cell lymphoma (PTCL) patients, in China on Dec. 23, 2014 by the Chinese Food and Drug Administration (CFDA).

International Collaboration Drives Discovery of Link Between Breast/Ovarian Cancer Gene and Stomach Cancer

BETHESDA, Md., Jan. 16, 2015 /PRNewswire-USNewswire/ -- A team of scientists from the United States and China has discovered new genetic insights that could change the way oncologists treat gastric cancer, the fourth most common cancer and the second leading cause of cancer death in the world. The investigators, who tested hundreds of gastric cancer tissue samples using advanced whole-genome sequencing technology, published their discovery online on January 12 in the Proceedings of National Academy of Sciences.

Pages